Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04WQJ
|
|||
| Former ID |
DIB013777
|
|||
| Drug Name |
AMG-181
|
|||
| Synonyms |
Inflammatory bowel disease therapeutics, Amgen
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Crohn disease [ICD-11: DD70; ICD-10: K50, K50.9; ICD-9: 555] | Phase 2 | [1] | |
| Ulcerative colitis [ICD-11: DD71; ICD-9: 556] | Phase 2 | [2] | ||
| Company |
Amgen; astrazeneca
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01696396) AMG 181 in Subjects With Moderate to Severe Crohn's Disease. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Pharmacology of AMG 181, a human anti-alpha4 beta7 antibody that specifically alters trafficking of gut-homing T cells. Br J Pharmacol. 2013 May;169(1):51-68. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.